About a month after Pfizer CEO Albert Bourla, Ph.D., told investors that the Big Pharma’s pipeline pruning was mostly done, ...

Pfizer PFE reported a 2% decline in revenue and a 4% increase in adjusted EPS in 2025, and management maintained 2026 revenue guidance for $59.5 billion-$62.5 billion (between flat and a 5% decline) ...

Pfizer Inc. Q4 shows post-COVID growth, Seagen-fueled oncology gains, and obesity upside. Click for this updated look at PFE ...

Pfizer's oncology pipeline looks promising. The company's newer approvals could make significant progress. And its efforts to reduce expenses should help it navigate tariff-related challenges. 10 ...

Daiichi Sankyo has emerged victorious in appeals court, flipping a prior multimillion-dollar patent verdict on its head and seemingly checking off the final box in its long-running legal fight with ...

Pfizer forecast modest 2026 guidance as it looks to counter waning Covid product sales and declines from older drugs with longer-term investments in its pipeline. The company expects adjusted profit ...

Pfizer’s PFE second-quarter 10% revenue growth and adjusted EPS of $0.78 were ahead of consensus expectations. Management maintained full-year revenue guidance of $61 billion-$64 billion and raised ...

Once a market darling during the early pandemic years, Pfizer (NYSE: PFE) has been on a straight southbound path for several years now. The company's shares are down by 50% since 2022. Some investors ...